Innate Pharma (IPHA) said Friday it is prioritizing its antibody-based NK Cell Engager platform to target hematologic cancers, solid tumors, and autoimmune diseases.
The company said it is currently testing its NK Cell Engager, IPH6501, in a phase 1/2 trial for non-Hodgkin's lymphoma.
Additionally, Innate said it is advancing its Antibody-Drug Conjugate programs, with lead candidate IPH4502 in a phase 1 trial for advanced solid tumors.
Innate is also seeking a partner for lacutamab in T-cell lymphomas and collaborating with AstraZeneca (AZN) on monalizumab, which is in a phase 3 trial for non-small cell lung cancer.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。